Literature DB >> 17467003

Expression of vascular endothelial growth factor and its receptors in canine lymphoma.

B Wolfesberger1, A Guija de Arespacohaga2, M Willmann3, W Gerner4, I Miller5, I Schwendenwein2, M Kleiter3, M Egerbacher6, J G Thalhammer3, L Muellauer7, M Skalicky8, I Walter6.   

Abstract

Vascular endothelial growth factor (VEGF) stimulates endothelial cell proliferation and has a pivotal role in tumour angiogenesis. The expression of VEGF and its receptors VEGFR-1 and VEGFR-2 was examined immunohistochemically in 43 specimens of canine lymphoma and in six normal lymph nodes. Western blotting and reverse transcriptase polymerase chain reaction (RT-PCR) were performed to detect VEGF protein and mRNA, respectively. VEGF protein was expressed by 60% of the tumours with diffuse cytoplasmic labelling of the neoplastic cells. Endothelial cells, macrophages and plasma cells were also immunolabelled. VEGFR-1 was expressed by variable numbers of neoplastic cells in 54% of lymphoma specimens. VEGFR-1 was also expressed by macrophages, plasma cells, reticulum cells, and vascular endothelial cells. Macrophages and lymphocytes in germinal centres of normal lymph nodes were also immunoreactive with anti-VEGF and VEGFR-1. Most tumours did not express VEGFR-2 but in 7% of sections there was focal labelling of neoplastic and endothelial cells, with a cytoplasmic and perinuclear pattern. The observed variability in expression of VEGF and its receptors probably relates to the fact that lymphoma is a heterogeneous lymphoproliferative tumour. Individual differences in VEGF and VEGFR expression must be taken into account when VEGF and VEGFR-targeted approaches for anti-angiogenic therapy are considered in dogs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17467003     DOI: 10.1016/j.jcpa.2007.03.003

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  4 in total

1.  Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs.

Authors:  Sofie Denies; Laetitia Cicchelero; Ingeborgh Polis; Niek N Sanders
Journal:  Oncotarget       Date:  2016-03-08

2.  Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.

Authors:  Hiroki Yamazaki; Naoki Miura; Yu-Chang Lai; Masashi Takahashi; Yuko Goto-Koshino; Momoi Yasuyuki; Munekazu Nakaichi; Hajime Tsujimoto; Asuka Setoguchi; Yasuyuki Endo
Journal:  J Vet Med Sci       Date:  2017-06-06       Impact factor: 1.267

3.  Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition.

Authors:  Hiroki Yamazaki; Yu-Chang Lai; Morihiro Tateno; Asuka Setoguchi; Yuko Goto-Koshino; Yasuyuki Endo; Munekazu Nakaichi; Hajime Tsujimoto; Naoki Miura
Journal:  PLoS One       Date:  2017-05-10       Impact factor: 3.240

4.  The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.

Authors:  Arianna Aricò; Mery Giantin; Maria Elena Gelain; Fulvio Riondato; Stefano Comazzi; Barbara C Rütgen; Sabine E Essler; Mauro Dacasto; Massimo Castagnaro; Luca Aresu
Journal:  BMC Vet Res       Date:  2013-05-03       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.